• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 7, 2013

View Archived Issues

Clinic Roundup

• Celtaxys Inc., of San Francisco, said it started a Phase I study of CTX-4430, which is designed to block pro-inflammatory enzyme leukotriene A4 hydrolase. The repeat-dose study is aimed at evaluating the safety, tolerability and pharmacokinetics of the drug and will enroll 96 subjects. Read More

Other News To Note

• Kinex Pharmaceuticals, of Buffalo, N.Y., said it has converted from a Limited Liability Corporation into a C-Corporation in a step to help drive future growth. Read More

Stock Movers

Read More

Swiss Kareus Therapeutics Aims Its KU-046 at Alzheimer's

Undeterred by the recent string of high-profile failures in the field, Kareus Therapeutics SA moved its first-in-class drug candidate for Alzheimer's disease, KU-046, into a Phase I trial in healthy volunteers. Read More

Synageva Upsizes Again and Seeks $100M in Public Offering

Synageva BioPharma Corp. took advantage of a 2 percent increase in its stock price during the New Year and bumped up the number of shares to boost the size of its public offering by 25 percent, from approximately 1.7 million shares cited in a preliminary prospectus supplement filed Thursday with the SEC to 2.15 million shares at Thursday's closing price of $47.53. Read More

Persistent Belief About Bacterial Persisters Is Found Incomplete

Bacteria have several ways to defend themselves against antibiotics. Out-and-out resistance through mutations in the bacterial genome is one. But there is a related phenomenon, persistence, that could perhaps best be described as "I'm not deaf; I'm ignoring you." Read More

Solstice Closes $18M Series A; Raises Stakes in RNAi Delivery

The promise of RNAi – the idea that specific genes can be pinpointed and silenced to treat disease – has loomed large on biopharma's radar for the past decade, even netting a 2006 Nobel to RNAi discoverers Craig Mello and Andrew Fire. Read More

Great Year on Capital Markets But Fundraising is a Challenge

Last year the prevailing global economic woes did not prove to be much of an impediment for biopharmaceutical companies in their quest to generate capital with a total of $24.8 billion raised. However, the ongoing financial uncertainties in Europe coupled with a weak domestic economy contributed toward making it a challenging environment for companies looking for funding. Read More

'Europe' a Creek, as Emerging Markets Letting Pharma Down

SAN FRANCISCO – At the lectern and away, talks at the 31st Annual J.P. Morgan Healthcare Conference are sure to concern the steadily worsening revenue shortfall, and how major pharma firms might satisfy profit-hungry shareholders as more casualties topple down the patent cliff. Read More

Bench Press: BioWorld Looks at Translational Medicine

Two independent teams, one from Johns Hopkins University and one from the University of California at San Francisco, contradicted earlier studies suggesting the kinase PKM-gamma is critical for learning and memory. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 14, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 14, 2025.
  • Circode executives

    Circode applies circRNA to heart disease drug R&D, in vivo CAR T

    BioWorld
    Shanghai Circode Biomed Co. Ltd. is set to begin clinical trials of HM-2002, a circular RNA (circRNA)-based drug for ischemic heart disease, having gained IND...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 15, 2025
  • Incurix describes new c-Myc inhibitors

    BioWorld Science
    Incurix Co. Ltd. has identified Myc proto-oncogene protein (c-Myc) inhibitors reported to be useful for the treatment of cancer.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe